ClinicalTrials.Veeva

Find clinical trials for Non-Hodgkin Lymphoma in Dallas, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoid Leukemia
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Dallas, TX, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Dallas, Texas, United States and 66 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Drug: Cyclophosphamide
Genetic: CB-010

Phase 1

Caribou Biosciences

Dallas, Texas, United States and 29 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Dallas, Texas, United States and 31 other locations

patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...

Active, not recruiting
Non-Hodgkin's Lymphoma
Small Lymphocytic Lymphoma
Drug: CG-806

Phase 1

Aptose Biosciences

Dallas, Texas, United States and 29 other locations

to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...

Enrolling
B-cell Non-Hodgkins Lymphoma (B-NHL)
Drug: Odronextamab
Drug: REGN5837

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Dallas, Texas, United States and 9 other locations

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non...

Active, not recruiting
NHL
NHL, Relapsed, Adult
Drug: CLN-978

Phase 1

Cullinan Therapeutics Inc.

Dallas, Texas, United States and 5 other locations

clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...

Enrolling
Non Hodgkin Lymphoma
Drug: Rituximab
Drug: Cyclophosphamide

Phase 1, Phase 2

Artiva Biotherapeutics

Dallas, Texas, United States and 20 other locations

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targ...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Drug: IMPT-314

Phase 1, Phase 2

ImmPACT Bio

Dallas, Texas, United States and 19 other locations

different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted e...

Enrolling
Refractory Non-Hodgkin Lymphoma
Advanced Solid Tumor
Drug: HCB101

Phase 1

FBD Biologics

Dallas, Texas, United States and 6 other locations

according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in eac-...

Enrolling
B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Dallas, Texas, United States and 137 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems